Skip to Main Content

Editor’s note: A recording of the conversation is embedded below.

Every week, STAT+ subscribers get access to exclusive content with biotech, pharma, and health tech leaders. This week, STAT’s senior writer of medicine and editorial director of events Matthew Herper will be joined by STAT’s national biotech reporter, Damian Garde. They will be discussing the FDA’s landmark decision to approve Biogen’s new Alzheimer’s drug, Aduhelm, and of course be taking your questions live.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment